Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
long-acting beta2-agonist + long-acting muscarinic antagonist
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
This is a **fixed-dose combination drug** comprising a long-acting beta2-adrenergic agonist (LABA) and a long-acting muscarinic antagonist (LAMA), both of which are used as inhaled bronchodilators for maintenance treatment of chronic obstructive pulmonary disease (COPD). LABAs stimulate adenylyl cyclase activity via beta2-adrenergic receptor agonism, directly causing airway smooth muscle relaxation. LAMAs inhibit acetylcholine at muscarinic (primarily M3) receptors, indirectly causing airway smooth muscle relaxation and reducing parasympathetic tone[1][2][5]. When combined, they provide superior bronchodilation and improve symptoms, lung function, and quality of life in COPD patients compared to monotherapies. These combinations are available in single inhalers and improve patient adherence and outcomes[1]. Commonly used long-acting drugs in these categories are indacaterol (LABA) and glycopyrronium (LAMA), among others[5].
- Brand names
- AnoroStiolto
- Other names
- laba/lamalaba-lamalong-acting beta-2 agonist and long-acting muscarinic antagonist combination
02
Targets
CHRM3 (M3)ADRB2 (β2)
Beyond the preview
Go deeper on long-acting beta2-agonist + long-acting muscarinic antagonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on long-acting beta2-agonist + long-acting muscarinic antagonist.